Prescribing, Policies and Pathways
or
Medicine / Guideline | Indication | RAG rating | Document type | Place |
---|---|---|---|---|
Abaloparatide | Osteoporosis after menopause | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Alendronic acid | Osteoporosis | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Armour thyroid | Hypothyroidism | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
Biosimilar insulins (Admelog Semglee and Trurapi) | Diabetes | Amber initiation | Decision document | Hertfordshire and West Essex ICB |
Bisphosphonates | Osteoporosis | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
Blood glucose and ketone meters, test strips and lancets | Diabetes | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
Blood glucose meters, test strips and lancets | Type 2 diabetes | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Blood glucose test strips and lancets quantity calculator | Diabetes | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
Calcium & vitamin D | Osteoporosis | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Canagliflozin | Chronic kidney disease | n/a | Prescribing pathway | Hertfordshire and West Essex ICB |
Continuous Glucose Monitoring - Adults - Initiation Specialist to GP letter | Diabetes | Amber initiation | Prescribing guideline | Hertfordshire and West Essex ICB |
Continuous Glucose Monitoring - Adults Policy | n/a | Clinical policy | Hertfordshire and West Essex ICB | |
Continuous Glucose Monitoring - Dexcom ONE to ONE+ Switch Letter to Patient | Diabetes | Amber initiation | Prescribing guideline | Hertfordshire and West Essex ICB |
Continuous Glucose Monitoring - Discontinuation Specialist to GP letter | Diabetes | Amber initiation | Prescribing guideline | Hertfordshire and West Essex ICB |
Continuous Glucose Monitoring - FSL2 to FSL2 Plus Sensor Switch Letter to Patient | Diabetes | Amber initiation | Prescribing guideline | Hertfordshire and West Essex ICB |
Continuous Glucose Monitoring - Paediatric - Initiation Specialist to GP letter | Diabetes | Amber initiation | Prescribing guideline | Hertfordshire and West Essex ICB |
Continuous Glucose Monitoring - Paediatric Policy | n/a | Clinical policy | Hertfordshire and West Essex ICB | |
Continuous Glucose Monitoring for patients with Type1 and Type 2 Diabetes | n/a | Patient information | Hertfordshire and West Essex ICB | |
Dapagliflozin | Chronic kidney disease | n/a | Prescribing pathway | Hertfordshire and West Essex ICB |
Dapagliflozin | Diabetes type 1 | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Denosumab | Osteoporosis | Amber initiation | Prescribing guideline | Hertfordshire and West Essex ICB |
Denosumab letter template | Osteoporosis | Amber initiation | Prescribing guideline | Hertfordshire and West Essex ICB |
Denosumab prescribing support document | Osteoporosis | Amber initiation | Prescribing support document | Hertfordshire and West Essex ICB |
Diabetes | n/a | Clinical pathways | South and West Hertfordshire | |
Diabetes - Structured Education for Type 2 | n/a | Patient information | East and North Hertfordshire | |
Diabetes New Patient Referral Pathway | n/a | n/a | Hertfordshire and West Essex ICB, South and West Hertfordshire | |
Diabetes type 1 | What to do when you are ill | n/a | Patient information | Hertfordshire and West Essex ICB |
Diabetes type 2 | What to do when you are ill | n/a | Patient information | Hertfordshire and West Essex ICB |
Diabetes type 2 | Diabetic ketoacidosis (DKA) | n/a | Patient information | Hertfordshire and West Essex ICB |
Dipeptidyl peptidase-4 inhibitors (Gliptins) | Diabetes type 2 | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Dual GIP with GLP-1 RA or GLP-1 RA with Insulin guidance document | Type 2 Diabetes | Amber initiation | Prescribing guideline | Hertfordshire and West Essex ICB |
Dual GIP with GLP-1 RA or GLP-1RA comparison document | Type 2 Diabetes | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
Empagliflozin | Chronic kidney disease | n/a | Prescribing pathway | Hertfordshire and West Essex ICB |
Exercise Protocol for the Management of CHD (Exercise for Cardiac Conditions) | n/a | Clinical pathways | East and North Hertfordshire | |
Foot Health for Diabetic Patients | n/a | Patient information | East and North Hertfordshire | |
Guidance for Self-monitoring of Blood Glucose (SMBG) for patients with Diabetes Mellitus | Diabetes | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
Hybrid Closed Loop Systems for Adults | n/a | Clinical policy | Hertfordshire and West Essex ICB | |
Hybrid Closed Loop Systems for Children and Young People aged under 19 years | n/a | Clinical policy | Hertfordshire and West Essex ICB | |
Hybrid closed loop systems for managing blood glucose levels | Diabetes type 1 | n/a | NICE technology appraisal | Hertfordshire and West Essex ICB |
Hydrocortisone (Alkindi) | Adrenal insufficiency | Double Red | n/a | Hertfordshire and West Essex ICB |
Hydrocortisone (Plenadren) | Adrenal insufficiency | Double Red | n/a | Hertfordshire and West Essex ICB |
Ibandronic acid - oral | Osteoporosis | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Ibandronic acid IV | Osteoporosis | Red | Prescribing guideline | Hertfordshire and West Essex ICB |
Insulin degludec (Tresiba) | Diabetes | Amber initiation | n/a | Hertfordshire and West Essex ICB |
Insulin Fiasp | Diabetes type 1 | Amber initiation | Decision document | Hertfordshire and West Essex ICB |
Insulin lispro (Lyumjev) | Diabetes type 1 | Double Red | n/a | Hertfordshire and West Essex ICB |
Insulin Pumps | n/a | Clinical policy | Hertfordshire and West Essex ICB | |
Ketone test strip | Diabetic ketoacidosis (DKA) sick day | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Liothyronine - Position Statement | Hypothyroidism | Amber protocol | Position statement | Hertfordshire and West Essex ICB |
Liothyronine – Information for Patients | Hypothyroidism | Amber protocol | Patient information | Hertfordshire and West Essex ICB |
Liothyronine in a selected cohort of adults with hypothyrodisim | Hypothyroidism | Amber protocol | Shared care protocol | Hertfordshire and West Essex ICB |
Liothyronine Review Algorithm | Hypothyroidism | Amber protocol | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
Liraglutide | Obesity in people aged 12 to 17 years | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Liraglutide | Overweight and obesity management | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Mecasermin | Growth failure (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
Mercaptamine | Corneal cystine deposits (NHSE) | Red | n/a | Hertfordshire and West Essex ICB |
Metformin | Diabetes type 2 | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
Naltrexone–bupropion | Overweight and obesity | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Needles for pre-filled / reusable insulin or GLP-1 receptor agonist pens | Diabetes | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
Needles Patient Information Leaflet | Diabetes | n/a | Patient information | Hertfordshire and West Essex ICB |
NICE NG28 Visual summary on choosing medicines for type 2 diabetes in adults | Type 2 diabetes | n/a | Prescribing pathway | Hertfordshire and West Essex ICB |
Osteoporosis | Osteoporosis | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
Paediatric preterm infants guidance | Paediatric Nutrition –Preterm | n/a | Decision document | East and North Hertfordshire, South and West Hertfordshire |
Paricalcitol | Hyperparathyroidism (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
Pen needles switch patient letter | Diabetes | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
Penicillamine | Tertiary care indication (NHSE) | Amber protocol | n/a | Hertfordshire and West Essex ICB |
Pre Diabetes | n/a | Patient information | Hertfordshire and West Essex ICB | |
Prednisolone | All indications - soluble tablet | n/a | Patient information | Hertfordshire and West Essex ICB |
Prednisolone enteric coated | All indications | Double Red | n/a | Hertfordshire and West Essex ICB |
Qtern | Diabetes type 2 | Double Red | Decision document | Hertfordshire and West Essex ICB |
Raloxifene | Osteoporosis | Amber initiation | Prescribing guideline | Hertfordshire and West Essex ICB |
Risedronate | Osteoporosis | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Romosozumab | Osteoporosis | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Safety needles letter | Diabetes | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
Semaglutide | Overweight and obesity management - adults | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Semaglutide | Overweight and obesity management - young people aged 12 to 17 years | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Semaglutide | Diabetes type 2 | n/a | Patient information | Hertfordshire and West Essex ICB |
SGLT2 inhibitors | Diabetes type 2 | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
Sitagliptin | Diabetes type 2 | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
Sitagliptin | Diabetes type 2 | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
Somatrogon (Ngenla) | Growth disturbance caused by growth hormone deficiency in children | Red | Decision document | Hertfordshire and West Essex ICB |
Strontium | Osteoporosis | Red | Prescribing guideline | Hertfordshire and West Essex ICB |
Teriparatide | Osteoporosis | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
Testosterone | Menopause | Amber initiation | Prescribing guideline | Hertfordshire and West Essex ICB |
Testosterone | Menopause | n/a | Patient information | Hertfordshire and West Essex ICB |
Testosterone gel | Menopause | Amber initiation | Decision document | Hertfordshire and West Essex ICB |
Tirzepatide | Overweight and Obesity | Double Red | n/a | Hertfordshire and West Essex ICB |
Tirzepatide | Diabetes type 2 | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
Tolvaptan | Kidney disease - autosomal dominant polycystic | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
Tolvaptan | Hyponatraemia secondary to SIADH | Red | Decision document | Hertfordshire and West Essex ICB |
Treatment for diabetic hypoglycaemia (hypos) - Position statement | Diabetes – Hypoglycaemia | n/a | Position statement | South and West Hertfordshire |
Trientine | Wilsons disease | Red | n/a | Hertfordshire and West Essex ICB |
Zolendronic acid | Osteoporosis | Red | Prescribing guideline | Hertfordshire and West Essex ICB |